TherapeuticsMD, Inc. (TXMD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 65 | 3 | 70 | 1 | 2 | 3 | 3 | 9 |
| Operating profit | $m | -4 | -4 | ||||||
| Net profit | $m | -184 | -172 | 112 | -10 | -2 | -1 | -0 | - |
| EPS reported | $ | -0.05 | -0.02 | ||||||
| Operating cashflow per share | $ | 0.21 | 0.23 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | 0.21 | 0.23 | ||||||
| Free cash flow | $m | 2 | 3 | ||||||
| Net debt | $m | -7 | -8 | ||||||
| Book value equity | $m | 27 | 27 | ||||||
| Book value per share | $ | 2.32 | 2.33 | ||||||
| Number of shares | m | 11.57 | 11.64 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 135.71 | ||||||
| P/B LTM | x | 0.70 | 0.70 | ||||||
| P/S LTM | x | 6.24 | 5.77 | ||||||
| P/FCF LTM | x | 7.78 | 6.04 | ||||||
| EV/EBITDA LTM | x | -5.78 | -4.16 | ||||||
| EV/Sales LTM | x | 5.78 | 6.41 | ||||||
| Earnings Yield LTM | % | -3.02% | +0.74% | ||||||
| FCF Yield | % | +12.85% | +16.55% | ||||||
| Quality | |||||||||
| ROE | % | -2.12% | +0.66% | ||||||
| ROIC | % | -12.45% | -8.10% | ||||||
| Operating margin | % | -1.39% | -1.12% | ||||||
| Gross margin | % | +100.00% | +90.31% | ||||||
| FCF/Sales | % | +80.21% | +79.75% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +71.61% | +85.69% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +231.15% | +326.23% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.40 | 0.56 | ||||||
| Net Debt/EBITDA | x | 0.46 | 0.75 | ||||||
| EBIT/Net interest | x | -526.75 | -624.00 | ||||||
| Net debt/market cap | % | 0.00% | +20.04% | ||||||
| Net debt/Equity | x | -0.28 | -0.30 | ||||||
| Gross debt/equity | x | 0.23 | 0.20 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free